The Role of the ANA Test for Arthritis and Autoimmune Disease

The blood antinuclear antibody (ANA) test is a diagnostic tool used to detect the presence of autoantibodies in the blood. Autoantibodies are antibodies that mistakenly target and attack the body’s tissues, leading to inflammation and damage. In the ANA test, these autoantibodies target the cell nucleus.

ANAs in the blood are often associated with autoimmune diseases, where the immune system mistakenly attacks healthy cells and tissues. These conditions involve chronic inflammation, which can affect various organs and systems in the body. Some common autoimmune diseases that may be detected through the ANA test include systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren’s syndrome, and scleroderma, among others.

The ANA Test for Diagnosing Autoimmune Disease

The ANA test confirms the presence of autoimmune disease and is a screening tool for determining whether further serological markers should be evaluated. The false positive and false negative rates of the ANA test can vary depending on the specific autoimmune disease being tested for.

Generally, the ANA test is known to have a relatively high false positive rate, meaning that it can detect the presence of autoantibodies in the blood even when the individual does not have an autoimmune disease. This can be due to various factors, such as infections, medications, or other non-autoimmune conditions that can trigger the production of autoantibodies.

On the other hand, false negatives, where the test fails to detect autoantibodies in individuals with an autoimmune disease, can also occur. This can be due to the variability in autoantibody levels, the specific type of autoantibodies present, or the timing of the test in relation to disease activity.

The ANA test’s false positive and false negative rates can differ between autoimmune diseases. For example, the ANA test is known to have a higher false positive rate in conditions like SLE, where autoantibodies are commonly detected. In contrast, diseases like Sjögren’s syndrome may have a lower false positive rate with the ANA test.

Monitoring the Course of Disease

Health care providers use the ANA test as an inflammatory marker to monitor the course of specific diseases, especially arthritis conditions. In arthritis, inflammation plays a key role in the progression of the disease and the severity of symptoms. By measuring ANA levels in the blood, providers can assess the level of inflammation present and adjust treatment accordingly.

For example, in RA, the ANA test can help differentiate it from other types of arthritis and provide valuable information about disease activity. High levels of ANAs may indicate more severe inflammation and disease progression, prompting the need for more aggressive treatment strategies. Conversely, low levels of ANAs may suggest that the disease is well-controlled and responding well to current therapies.

Differentiating Autoimmune Disease versus Degenerative Disease

The ANA test helps differentiate different types of arthritis by detecting the presence of specific autoantibodies that target the cell nucleus. Each autoimmune disease, including various types of arthritis, has its unique autoantibodies associated with it. For example, anti-citrullinated protein antibodies (ACPAs) in the blood are a hallmark of rheumatoid arthritis (RA). In contrast, antinuclear antibodies are commonly found in systemic lupus erythematosus (SLE).

In a literature review, positive ANA test results should lead to further specific tests. In contrast, a negative ANA is supposed to rule out other underlying autoimmune disorders.¹  Unfortunately, the ANA test may be positive or negative in RA patients. In one study of 161 RA patients, only 25% were ANA positive. Significant differences were noted between ANA positive and ANA negative regarding time to meet RA diagnostic criteria and time to treatment, which may suggest a difference in clinical presentation.²

In comparison, osteoarthritis typically does not show elevated levels of ANA in the blood. Osteoarthritis is a degenerative joint disease not considered an autoimmune condition like rheumatoid arthritis or lupus. As such, it is not typically associated with the presence of autoantibodies detected by the ANA test. Instead, osteoarthritis is characterized by the breakdown of cartilage in the joints, leading to pain, stiffness, and decreased mobility.

Over-utilization of testing without clinical indications may increase patient anxiety and increase health care costs. As ANA has a low positive predictive value, clinicians must order testing appropriately. ³

Summary

By measuring ANA levels in the blood, health care providers can identify which specific autoantibodies are present, thus helping to differentiate between different types of autoimmune arthritis and other autoimmune diseases. This information is crucial for making an accurate diagnosis and determining the most appropriate treatment plan for the patient. Additionally, the ANA test can also provide insights into the level of inflammation and disease activity, which further aids in distinguishing between different types of arthritis and guiding treatment decisions.

Overall, the ANA test is a valuable tool, along with other markers and clinical evaluation, in diagnosing and managing autoimmune diseases, particularly arthritis conditions. By monitoring ANA levels, healthcare providers can assess inflammation, track disease progression, and tailor treatment plans to manage symptoms and improve patient outcomes.

References

1.         Wedari NLPH, Budayanti NNS, Sukrama IDM, Mayura IPB. Implementation of antinuclear antibodies in autoimmune diagnostic tests: a literature review from immunological aspects antibodies in autoimmune diagnostic tests: a literature review from immunological aspects. Journal of Clinical Microbiology and Infectious Diseases (JCMID) 2022. 2022;2(2).

2.         Paknikar SS, Crowson CS, Davis JM, Thanarajasingam U. Exploring the Role of Antinuclear Antibody Positivity in the Diagnosis, Treatment, and Health Outcomes of Patients With Rheumatoid Arthritis. ACR Open Rheumatol. 2021;3(6). doi:10.1002/acr2.11271

3.         Ahrari A, Barrett SS, Basharat P, Rohekar S, Pope JE. Appropriateness of laboratory tests in the diagnosis of inflammatory rheumatic diseases among patients newly referred to rheumatologists. Joint Bone Spine. 2020;87(6). doi:10.1016/j.jbspin.2020.05.007